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Abstract
Purpose: Dense breast tissue is an independent risk factor for breast cancer and lowers the
sensitivity of screening mammography. Supplemental screening with ultrasound or MRI
improves breast cancer detection rate but has potential harms. Breast density notification
(BDN) legislation has been introduced in the United States (US) and its impact on
supplemental screening practices is unclear. This study systematically reviewed current
evidence to explore the impact of BDN on supplemental screening practices in the US.
Methods: Medline, PubMed, Embase, Cochrane and the Cinhal Library databases were
searched (2009-August 2020). Studies were assessed for eligibility, data were extracted and
summarised, and study quality was evaluated.
Results: Evidence from the included studies (n=14) predominantly showed that BDN
legislation increased the overall utilisation of supplemental screening by 0.5-143%. This
effect was amplified if the notification included a follow-up telephone call informing women
about additional screening benefits, and if the state’s law mandated insurance cover for
supplemental screening. Likelihood of supplemental screening was also influenced by history
of breast biopsy and family history of breast cancer, race, age, socioeconomic status, density
category, and physician’s specialty and region. Some studies reported increases in biopsy rate
(up to 4%) and cancer detection rate (up to 11%) after implementation of BDN legislation.
Conclusion: BDN leads to increased use of supplemental screening. This has implications for
women and the health system. These findings can help inform current and future screening
programs where breast density notification is currently implemented or being considered.
Keywords: breast density, mammography, notification, legislation, supplemental screening
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Background
Breast density refers to the proportion of fibrous and glandular tissue relative to fatty tissue
on mammography. The American College of Radiology’s Breast Imaging Reporting and Data
System (BI-RADS) includes four categories of density: almost entirely fatty, scattered areas
of fibro glandular density, heterogeneously dense, or extremely dense [1]. Women with dense
breast tissue (in the heterogeneously dense or extremely dense categories) make up around
43.3% of women aged 40 to 74 years in the United States (US) [2], and it has been estimated
that 27 million women in the US have heterogeneously or extremely dense breasts [2]. Breast
density is relevant because dense breast tissue can mask cancers on mammograms. The
overall sensitivity of mammography for the detection of breast cancer has been shown to
reduce by 20-40% in women with dense breast tissue [3, 4]. Also, it has been identified as an
independent risk factor for breast cancer [5].
With the aim of providing more health information to women to allow them to make
informed decisions about their breast health, breast density notification (BDN) legislation has
been introduced in more than 30 states since 2009, and the US Congress passed federal BDN
in February 2019 [6]. These laws require facilities performing mammography to include
breast density information in reports sent to patients and physicians. There is variation in how
states implement notification [7]. In some states, such as New Jersey and Texas, all women
who undergo screening receive information about breast density; however, in other states
including California and Michigan, only women classified as having dense tissue are notified
[7]. The notification includes information about potential health risks of dense breasts, and a
recommendation for further consultation with physicians or for supplemental screening in
some states such as North Carolina and Oklahoma, however, in other states women only are
informed of breast density without accompanying recommendations for management [7].
Currently, only three states (Connecticut, New York, New Jersey) have laws that require
health insurance cover for supplemental screening.
One strategy for managing dense breast tissue is for women with normal conventional
mammography and dense breasts to undergo additional (supplemental) screening with other
imaging modalities (ultrasound, MRI, and/or tomosynthesis). Currently, clinical guidelines
that make explicit recommendations about management of breast density and how to use
supplemental screening are lacking. This means that clinicians and women and the clinicians
guiding them do not have specific guidance about how to manage the risk associated with
dense breast tissue. Although supplemental breast screening using additional screening
modalities, for women with no symptoms and normal mammography but dense breast tissue,
has been shown to improve cancer detection rates [8–10], these tests also have important
potential harms including false-positive results, unnecessary biopsies and overdiagnosis of
breast cancer [11, 12]. Adding screening ultrasound to mammography for dense breast
women increases detection rates of breast cancers, but results in more than double the risk of
a false‐positive biopsy [13]. Furthermore, in cost-effectiveness analysis, supplemental
screening may significantly increase expenditures while producing limited health benefits
[14, 15]. BDN also may increase women’s confusion and anxiety [16, 17], and this may
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increase women’s intention to take up additional screening. This therefore puts into question
the value of widespread BDN legislation [18].
This systematic review aimed to evaluate the impact of BDN legislation on supplementary
screening practices in the US. Secondary aims were to assess the recall rates and incremental
cancer detection related to supplementary screening and to identify other potential impacts on
women and the health care system.
Methods
This review has been registered with PROSPERO (Registration ID: CRD42020204041).
Data Source and Searches
Medline, PubMed, Embase, Cochrane and the Cinhal Library were searched for relevant
English-language studies. The search was conducted between 2009 (when the first BDN
legislation passed in the US) and August 18, 2020. The search strategy is described in detail
in Supplementary file 1 (Online Resource).
Eligibility Criteria and Study Selection
Empirical studies reporting the impact of breast density notification or legislation on
supplemental screening practices were included. Studies were eligible if they included
populations of women with a normal (‘negative’) screening mammogram and reported on the
uptake of supplemental screening (ultrasound, MRI or breast tomosynthesis) and provided
data on the effect of implementation of legislation. Inclusion was not limited to studies of
women with dense breasts and was not limited to studies that presented data both pre- and
post- implementation of legislation.
Conference abstracts, protocols, review papers, commentary papers, hypothetical studies and
studies that measured only intention to use additional imaging were excluded.
Studies identified in the initial search and by full-text were assessed by two investigators (SH,
BN) to ensure eligibility according to predetermined criteria (Supplementary file 2, Online
Resource). Any disagreement was checked by an additional investigator (MB) for
consideration in the final study.
Data Extraction and Quality Assessment
A data extraction template was created in Excel. Data were extracted by one investigator (SH)
and checked for accuracy by another (BN). Data were collected on key characteristics of
eligible studies (population, methodology and BDN information) and results (use of
supplemental ultrasound, MRI and/or breast tomosynthesis). If available, data on secondary
outcomes were extracted: recall for further assessment for each supplementary modality,
biopsy or cancer detection for each supplementary modality, financial cost, or patient report
outcome measures related to additional screening.
Due to the heterogeneity of the methods of included studies, The Joanna Brigg’s Institute
(JBI) critical appraisal tools were used for quality (risk of bias) assessment as these provide
criteria for the assessment of different study types. [19]. Each study was appraised by two
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investigators independently and then checked by a third if needed. The criteria for overall risk
of bias assessment were: Low: the study meets all criteria or only has one “Unclear” item;
Moderate: the study has one “No” item and less than two “Unclear” items; and High: the
study has more than two “No” (any number of “Unclear” items). “Not applicable” wasn’t
used to determine risk of bias category. All studies, regardless of their quality, were included
in the analysis.
Results from the studies were synthesised in a narrative form, as the heterogeneity of the
studies did not support pooling of results [20].
Results
Study Search and Selection Results
The initial search results yielded 432 articles; 4 additional articles were identified through
hand searching of reference lists. After removal of duplicates (n=263), 173 articles were
screened by titles and abstracts for eligibility. Twenty articles were included in the full-text
review, of which 14 studies were identified for final inclusion (See PRISMA flowchart [21]
in Figure 1).
Characteristics of Studies
Table 1 summarises the characteristics of the included studies. Nine studies were set in one of
the states in the US, 6 [22–27] of those set in a single medical centre, and three others [28–30]
used data from databases that included many facilities in their state. The states included
Kansas [22], Michigan [23], Connecticut [25], Texas [24], California [26, 28], North Carolina
[29] and New Jersey [27, 30]. There were five nationwide studies, collecting data through
pre-existing survey systems [31, 32] or health insurance databases that cover the whole US
population [33–35], to carry out a state-level analysis. The most common modalities assessed
in the studies were ultrasound and MRI. The majority of studies examined the impact of BDN
through pre-and post-legislation comparison.
The included sample sizes ranged from 751 to 2,600,370 women. Six studies were deemed to
be of low risk of bias [23, 28, 29, 32, 34, 35], four studies moderate [22, 25, 26, 31] and four
studies high [24, 27, 30, 33]. The age of participants ranged from 40 to 70 years. There was a
greater proportion of white participants in all studies which reported the proportion of race
[22, 23, 26, 28, 29, 31, 32]. Although half of the studies didn’t report the proportion of
women with dense breasts, both women with dense breasts and non-dense breasts were
included in all studies. Therefore, all studies considered the effects of BDN for all women and
not just for women with dense breasts.
The law that requires health insurance cover for supplemental screening tests affects
utilisation of supplemental screening. Two studies had stratification analysis after stratifying
women from states that have laws requiring insurance cover for supplemental screening [31,
35]. To control potential for confounding, the Busch et al. study omitted women residing in
the states where these laws are in place [33]. Three studies included an entire cohort residing
in New Jersey and Connecticut, states that have mandatory insurance coverage for
supplemental screening [25, 27, 30].
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Main Results of Studies
Table 2 summarises the main results of the studies, including factors associated with
supplemental screening utilisation. Table 3 summarises the studies that reported statistically
significant increases in supplemental screening utilisation as an outcome of BDN. Except for
the studies conducted by Aripoli et al. [22] and Aminawung et al. [31], all studies reported
their data into two periods, before and after the implementation of BDN legislation, then
compared supplemental screening utilisation between the two periods to examine the effect of
BDN legislation. Aripoli et al. assessed the impact of three types of BDN, provided by three
radiologists, on ultrasound utilisation rates [22]. Aminawung et al. made comparison among
different states which had different types of BDN and law’s requirement [31]. Busch et al.
[35] and Saulsberry et al. [33] compared the effect of BDN pre- and post-legislation and also
included a comparison of utilisation of supplemental screening between states.
Supplemental Screening Utilisation
The utilisation of supplemental screening, regardless of whether this was ultrasound, MRI or
breast tomosynthesis, increased after the enactment of BDN legislation in all studies (Table
3), except in the study by Nyante et al. which reported similar utilisation rates before/after
legislation [29]. The overall rates of supplemental screening increased by 0.5-143% (median:
16%) after legislation [23–25, 27–29, 32–35]. There was an increase of 0.81-11.2% per
mammographic study in supplemental screening rate in two studies [28, 33]. Two other
studies [26, 30] showed a 29-651% increase in the total number of breast screening
examinations performed after legislation. The increases found in these two studies were not
limited to supplemental screening but indicated an uptake in breast screening overall (Table
3). Aripoli et al. [22] and Aminawung et al. [31] studies suggested women who received BDN
or lived in states with BDN legislation were more likely to receive supplemental screening
(P<0.001).
According to the 5 national-level studies [32–35], BDN legislation led to an increase in the
utilisation of supplemental screening in most states. Choudhery et al. [36] suggested there
was a significant relationship between the implementation of BDN legislation and the
utilisation of supplemental screening (p<0.05). However in the study by Liao et al. [32], the
overall rates of screening ultrasound increased after the adoption of BDN legislation but
remained generally low over time, suggesting that there was no significant association
between the adoption of BDN legislation and screening ultrasound (RR: 1.4, 95% CI: 0.4-4.4,
p=0.56) [32]. Six of fourteen studies [23–27, 30] did not report whether the increases they
identified in the utilisation of supplemental screening were statistically significant (Table 3).
Factors which are associated with the likelihood of utilisation
Findings from 6 studies [22, 23, 26, 28, 29, 32] demonstrated that the likelihood of
supplemental screening utilisation was associated with patient-level variables including
history of breast biopsy and/or family history of breast cancer, race, age, socioeconomic
status and breast density, and physician’s specialty and region. Women with medical and
family history [22], younger age [28, 32], the higher level of socioeconomic status [28] and
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dense breast tissue [23, 28, 29] were more likely to receive supplemental screening when
compared to women without these characteristics. Compared to women of other races (Black,
Asian), white women were more likely to have supplemental screening [23, 26, 28]. Manning
et al. [23] suggested that African American women were less likely to have supplemental
screening both before and after the BDN legislation compared to European Americans.
However, the increase in supplemental screening rate was more evident in African Americans
after legislation. The study indicated a 5-fold post-law increase in supplemental screening
rate, attributable to the increase in the proportion of African Americans who had
supplemental screening after the adoption of BDN legislation. This study also suggested that
African American women were less likely to have dense breast and breast cancer compared to
European Americans, which contributed to between-race differences in the supplemental
screening rate. Liao et al. [32] and Ram et al. [26] found that female physicians and
specialists were more likely to request supplemental screening for women with dense breasts
compared to male and primary care physicians. Liao et al. [32] also indicated physicians in
urban areas more frequently requested supplemental screening for their patients than those in
rural areas.
The Impact of Different Breast Density Notifications/ Notification Legislation
Table 4 summarises studies that compared the effect of different types of breast density
notifications or legislation on supplemental screening. These studies indicated that the impact
of BDN may be amplified if notification includes a follow-up telephone call and information
about additional screening benefits, and if the state’s law requires insurance cover for
supplemental screening [22, 31, 33, 35]. When BDN was followed by a courtesy telephone
call [22] and informed women of the potential benefits of additional screening [22, 31, 33],
increases in supplemental screening rates was more evident, compared to notification without
these follow-up practices. Women from states with mandatory insurance coverage for
supplemental screening were more likely to undergo supplemental screening, compared to
other states [31, 35]. Nyante et al. [29] suggested that one of the reasons why supplemental
screening utilisation didn’t significantly increase in North Carolina was that this state’s law
did not require such insurance coverage.
Secondary Outcomes (Biopsy and Cancer Detection Rate from supplemental screening
following normal screening mammography)
Three studies [25, 30, 35] found BDN to be associated with higher biopsy and cancer
detection rates. Biopsy rates increased by 0.4%-4% after BDN legislation [25, 30, 35]. Parris
et al. reported that cancer detection rate with ultrasound increased from 0% to 0.18% during
the study period in their institution [25]. Sanders et al. also found screen-detected cancers
increased by 11% after BDN legislation (P<0.01) [30]. The increases in biopsy and cancer
detection rates after implementation of BDN legislation were generally small in magnitude,
and another study [33] showed no statistically significant changes in biopsy and cancer
detection rates after legislation.
Discussion
5

This systematic review found that overall BDN legislation increased the utilisation of
supplemental screening, but that effect ranged broadly between 0.5-143%. Both state-specific
and national studies showed similar increases in the utilisation of supplemental screening
after the implementation of BDN legislation, with only one study not showing an increase.
That one study by Nyante et al. that didn’t observe an increase in supplemental screening had
a short study period, underscoring that changes in supplemental screening utilisation may
require evaluation over a longer period of time[29]. The main concern for the studies
performed in one of the states in the US [22–30], especially for those set in a single institution
[22–27], was their findings might not be generalisable to other states, particularly where
health insurance coverage requirement differe from state to state.
The finding that patient-level factors including history of breast biopsy and/or family history
of breast cancer, race, age and breast density were shown to be associated with supplemental
screening uptake [22, 23, 26, 28, 29, 32], is similar to previous findings in the context of
mammography screening [37–39]. Women with higher socioeconomic status were also more
likely to receive supplemental screening [28]. One reason for this could be that women with
less education, lower incomes, and non-white race/ethnicity may be less familiar with the
concept of breast density [40–42] and this may make them less empowered to initiate a
discussion about density and supplemental screening with their physicians. Furthermore,
women were more likely to receive supplemental screening in states which have laws
requiring insurance coverage for these tests [31, 35], if they receive care from a female
physician [26] and if they are attending a facility in an urban location [32]. A survey
conducted to assess women’s interest in breast density and attitudes to supplemental
screening showed that only 22% women from the rural facility and 70% women from urban
facility were willing to pay for supplemental testing [43].
Currently, the content of BDN is variable, and a more consistent content is lacking which is
worrying given that increases in supplemental screening utilisation were also reported to be
more evident among states where notification includes information on the benefit of
additional screening [22, 33].
Together these findings imply that there are both socioeconomic and demographic disparities
in screening that may be amplified by BDN legislation. Furthermore, difficulty understanding
the concept of breast density, as well as the absence of health insurance coverage of
supplemental breast imaging in many states may add to these disparities. The content of BDN
and how it is distributed to women should be taken into account in advance by stakeholders
and be designed to fit the specific healthcare system.
Importantly, there was evidence from the included studies of a slight increase in biopsy and
cancer detection rates after BDN legislation [25, 30, 35]. While these findings are consistent
with previous research [44], it is unknown whether this translates to improved health
outcomes. As BDN increases supplemental screening uptake, it also increases false-positive
findings [11, 13]. This may increase physical and/or psychological harms caused by
additional screening and unnecessary biopsy, as well as the potential for overdiagnosis and
overtreatment of breast cancer, and an additional financial cost for women [13, 16, 45, 46].
Evidence on the efficacy of different screening modalities, including long-term outcomes, is
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required to support consistent clinical guidelines on supplemental screening for women with
dense breasts.
The utilisation of medical imaging is increasing in the US [47]. BDN legislation may
potentially lead to a considerable economic burden to the healthcare system and the
community based on the costs of additional screening for dense breast women [48]. One
study in this review estimated increased direct cost for insurers of $4,910,899 to $9,848,897
for a given month following enactment of BDN legislation [27]. The addition of MRI
increased the cost per patient screened from $176 for mammography alone to $571 for the
combination [45]. Because of the significant economic burden, stakeholders may need more
evidence on cost-effectiveness to support their decision on the implementation of BDN
legislation.
Limitations
Current evidence regarding the impact of BDN legislation outlined in this review is
predominantly from retrospective studies that sourced data from institutional or health
insurance databases or surveys and compared data pre-and post-legislation or among states.
Meta-analysis was not appropriate for this review and increases in ultrasound and MRI
utilisation were shown to have a broad range across studies, and six studies [23–27, 30] didn’t
report the statistical significance of the increased utilisation attributed to BDN. We used the
JBI critical appraisal tools to assess and descriptively report study quality. As a meta-analysis
was not conducted we were unable to test the differences in study quality analytically so this
did not did not preclude inclusion of any studies.
Although the effect of BDN generally showed increased supplemental screening utilisation,
this may be confounded by unknown factors; utilisation of breast imaging examinations may
be for various purposes and not only due to dense breasts or notification. Therefore, it may be
questioned whether studies isolated the impact of BDN legislation on the likelihood of
supplemental screening. Little is known about the factors driving recommendations beyond
BDN legislation. However, this is the first systematic review to synthesise current evidence
on the impact of BDN legislation on supplemental screening utilisation.
Conclusion
This review shows that BDN legislation increased supplemental screening utilisation. This
information is relevant for current and future screening programs and services which have
already implemented or are considering implementing breast density notification and/or
legislation. Stakeholders should carefully consider the factors identified as potentially
impacting BDN practice, including patient-level factors, notification content, distribution
modality, physician’s specialty, region, and insurance coverage in order to maximise the
intended benefit and reduce the harms. Further research could focus on determining the
potential benefits and cost-effectiveness of BDN legislation, and the down-stream
consequences of providing different supplemental screening modalities at a population level.
Funding Information: Nehmat Houssami is supported by a National Health and Medical
Research Council (NHMRC) Investigator (Leader) Grant #1194410
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Fig. 1. PRISMA flowchart showing results of literature search and assessment of studies [21]
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Table 1. Characteristics of included studies on supplemental screening practice in response to BDN (n=14)
Study

State

Study aim

Study

(author,

design/setting and

year)

sample size

Population characteristics

Pre/Post
notification vs.

Insurance
coverage

(1)

Supplemental screening

Secondary

Risk of

utilisation assessed

outcomes

bias [19]

assessed



Age

state notification

Ultra-



Race

comparison

sound



Percentage of dense

MRI

Breast
tomosynthesis

breast
To assess the effect

Review data from



Age range: 55.8±11.0

Neither

al., 2018

of three types of

the University of



Race: 65.0% White,

(comparison

[22]

breast density

Kansas Medical

8.1% Black, 2.4%

among three types

notification on

Centre.

Hispanic or Latino,

of breast density

automated

751 women.

3.9% other, 19.7%

notification

unknown

provided by three

Percentage of dense

radiologists)

Aripoli et

Kansas

screening breast


ultrasound
utilisation rates.
Aminawung

Nationwide

To examine the



No

Moderate

breast: Not reported
National survey




State notification

40 to 60

et al.，

association between

through the Growth

2020 [31]

different types of

from Knowledge

Black, 15.0% Hispanic,

BDN legislation

(GfK)

9.0% Other 62.7%

and supplemental

KnowledgePanel®.

screening

1545 women

62.6% White, 13.4%

Stratification









Moderate

(2)

comparison

analysis

Both

All women

behaviours among
women.
Busch et al.,
2019 [33]

Nationwide

To evaluate the

Review data from



Age range: 40 to 59

association of state

the Blue Cross Blue



Race and Percentage of

covered by

BDN notification

Shield Alliance for

dense breast: Not

private

legislation with the

Health Research.

reported

insurance.

use of supplemental

1,441,544 screening

Exclude
14

Biopsy

High

tests and cancer

mammograms

women from

diagnosis after

among 1,160,079

states with

screening

women from 34 US

mandatory

mammography.

states.

insurance
coverage for
supplemental
screening

Chau et

Northern

To examine the

Review data from



Age range: 40-74

Pre/Post

al.,2017

California

impact of the

the Permanente



Race: 68.9% White,

notification

California BDN

Medical Group

17.4%Asian,

comparison

legislation on rates

(TPMG) Breast

3.5%Black, 9.9%

of screening

Cancer Tracking

Hispanic, 0.3%Native

mammography and

System (BCTS).

American

MRI, focusing on

631,478 Women,

the 2 years before

872 screening MIR

[28]



No



Low



Low

Percentage of dense
breast: 42%

and 2 years after
BDN legislation.
To test whether

Review data from



Age range: 40 to 64

Pre/Post

All women

al., 2020

BDN legislation

the Truven Health



Race and Percentage of

notification

covered by

[34]

affected the

MarketScan®

dense breast: Not

comparison

private

probability of

Commercial Claims

reported

screening

and Encounters

Most included

mammography

Databases.

states did not

follow-up by

10,265,216

mandate

ultrasound and MRI

screening

insurance

mammograms

coverage for

Horny et

Nationwide

insurance.

supplemental
screening.
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To describe factors

Review data from



Age range: 40 to 70

Pre/Post

associated with

the National



Race: 78% White, 10%

notification

screening

Ambulatory

black, 8% Hispanic,

comparison

ultrasound ordering

Medical Care

4% other.

and determine

Survey (NAMCS).

whether adoption of

12,787 NAMCS

state-level

office visits.

To examine the

Review data from



Mean age: 60.21

Pre/Post

al., 2019

between-race

the cancer centre’s



Race: White 20%,

notification

[23]

differences in

breast clinic in

Black 80%

comparison

supplemental breast

midtown Detroit,

screening before

Michigan. 2,764

and after BDN

African American

legislation

women, 691

Liao et al.,

Nationwide

2020 [32]

Manning et

Michigan



Not reported



No



Low

Percentage of dense
breast: Not reported







Low

Percentage of dense
breast: 23.2%

European American
women
Mason et

Texas

To evaluate the

Review data from

Not reported

Pre/Post

al.， 2015

trend in the number

Baylor University

notification

[24]

of screening MRIs

Medical Centre at

comparison

at Baylor University

Dallas.

Medical Centre

902 MRI

Nyante et

North

To investigate

Review data from



Age range: 40 to 79

Pre/Post

al., 2020

Carolina

supplemental

the Carolina



Race: Before the law:

notification

screening before

Mammography

71% White, 26%

comparison

and after BDN

Registry. 145,279

Black, 2% Other;

legislation in North

screening

After the law: 68%

Carolina

mammograms

White, 29% Black, 2%

[29]

Other
16



No

No





High



Low

among 30,850



women
Parris et al.,

Connecticut

2013 [25]

Ram et al.,

California

2018 [26]

Percentage of dense
breast: 30.7%

To evaluate the

Set at Norwalk



Age range: 50 ±10

Pre/Post

benefits of

Radiology and



Race:

notification

cancer

screening breast

Mammography

Not reported

comparison

detection

ultrasound in

Centre. Review

women with dense

data from the

breast: 77% before law;

breast tissue

Magview, health

85% after law

following

care information

enactment of

management

Connecticut Bill

systems.

458

6368 women

To assess the

University of



Age range: 50 ±10

Pre/Post

impact of

California Davis



Race: 71.8% White,

notification

California’s Breast

Medical Centre.

3.7% Black, 2.4%

comparison

Density Law on

1022 MRI

Other





MRI utilisation and
clinician ordering

Yes



Biopsy and

Moderate

Percentage of dense



Not reported

Moderate

Percentage of dense
breast: 62.9%

practices
To examine the

Review data from



Age range: 40 to 64

et al., 2019

effects of state BDN

Thomson Reuters’



Race and Percentage of

[35]

legislation on the

MarketScan®

dense breast: Not

use of supplemental

database. 2,600,370

reported

breast imaging and

women in 12 states

breast biopsies.

with BDL laws.

Saulsberry

Nationwide

Both

Stratification
analysis(2)







Biopsy and
cancer
detection

920,785 women in
12 matched control
states.
17

Low

Sobotka et

New Jersey

To examine the

Set at Hackettstown

Not reported

Pre/Post

al., 2015

effect of BDN

Regional Medical

notification

[27]

legislation on

Centre,

comparison

mammography,

Hackettstown.

follow-up

About 415 per

ultrasound and

month at this

estimate the

institution.

Yes



Financial

High

ramifications

legislation’s direct
financial
ramifications.
To assess the

Review data from



Age range: 40 to 64

Pre/Post

al., 2016

impact of the

the Breast Centre,



Race and Percentage of

notification

cancer

[30]

NJBDL at one of

Barnabas Health

dense breast: Not

comparison

detection,

the state’s largest

Ambulatory Care

reported

ACR-accredited

Centre Livingston.

breast centres

5923 screening

Sanders et

New Jersey

Yes







Biopsy,

High

efficacy of
modality

imaging cases,
1213 cancer cases.
Notes: (1) whether state’s law requires health insurance cover for supplemental screening; (2) studies included stratification analysis for states that had laws requiring mandatory insurance for supplemental
screening
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Table 2. Study-specific measures and results of studies on supplemental screening practice in response to BDN
Study

Measure

Main outcome results

Factors associated with the likelihood of

(author,

supplemental screening utilisation (if applicable)

year)
Aripoli et

Examine the association between three types of letters



Patients who received letter B and letter C were 9.91 times (95%
(1)

History of breast biopsy and family history of breast

al., 2018

and receipt of supplemental screening.

CI : 6.08–16.16) and 75.51 times (95% CI: 40.88–128.62) more

cancer were significant predictors of returning for a

[32]



Letter A: no notification of breast tissue density

likely to return for supplemental ultrasound examination than were

supplemental ultrasound (P<0.05).



Letter B: notification of breast tissue density;

patients who received letter A.

benefits from additional screening




Significantly greater proportion of patients who received letter C

Letter C: notification of breast tissue density;

returned for supplemental ultrasound (86.9%) compared with

information on benefits from additional screening; a

patients receiving letter A (9.7%) and letter B (48.8%) (P<0.001).

follow-up courtesy telephone call
Aminawung

Group women by state BDN, then, compare the

Women who lived in BDN-coverage states were also more likely to

et al., 2020

supplemental screening behaviours between different

have received supplemental screening (19.3%) compared to women

[31]

groups

living in non-BDN (9.9%); contrast 9.4% (95% CI:1.6%-17.3%;



Non‐BDN States

(2)

Not reported

P=0.01), Generic BDN (7.3%); contrast 12.0% (95% CI: 4.6%-19.4%;



Generic BDN States : breast density

P<0.001), and BDN-SS (8.8%); contrast 10.5% (95% CI: 2.6%-18.5%;



BDN‐SS States : breast density and benefits of

P<0.01) states.

(3)

(4)

supplemental screening


BDN‐coverage States(5): breast density notification
with mandated insurance coverage for supplemental
screening

Busch et al.,

1.

2019 [33]
2.

Compare the utilisation of ultrasound, MRI(6),

1. Comparisons between two periods (rate of supplemental testing)

biopsy and cancer detection in a post-legislation



experienced a very small but

period with a pre-legislation period.

statistically significant 0.81 per 1000 increase in supplemental

Compare the utilisation between states with

MRI (95% CI: 0.10, 1.5 per 1000)

different types of BDN legislation.


Generic BDN legislation states

(3)

No BDN legislation in effect: 25 states



BDN+SS legislation states(4) experienced a statistically significant
11.2 per 1000 mammograms increase in supplemental ultrasound
19

Not reported



Generic BDN legislation with no mention of the

(95% CI: 8.6, 13.7 per 1000), with no statistically significant

possible benefits of supplemental screening:

changes in other outcomes studied.

Arizona, Ohio, Minnesota, North Dakota,




For each of the 4 outcomes, parallel trends tests indicated that in

Tennessee

the first 6 months of the study, there were no significant

BDN legislation with mandated notification of the

differences in trends across the 3 categories of BDN legislation.

possible benefits of supplemental screening:

2.

Massachusetts, Michigan, Missouri, Rhode Island



Comparisons between states
Supplemental ultrasound was significantly higher among screening
mammograms performed in states with BDN+SS legislation than
among those performed in no legislation states (10.5 per 1000;
95% CI: 2.95, 17.6 per 1000; P: 0.006) and generic BDN
legislation states (9.2 per 1000; 95% CI: 1.31, 16.7 per 1000;
P=0.02).



No significant differences in the supplemental MRI rate across
categories of BDN status.



No significant differences in biopsy across categories of BDN
legislation.

Chau et



Compare the crude rate in pre- and post-legislation.

al.,2017 [28]



Calculate relative risk comparing MRI rate in both

(95% CI 11.2-13.0) to 13.8 per 10 000 women (95% CI 12.9-14.7)

for Asian and white women, women aged 42

periods

(P=0.008).

to 44 years, women with normal BMI(9), and

A relative 16% increase (RR(7): 1.16, CI: 1.07-1.25) in the MRI

women living in neighbourhoods with a

rate (P<0.001).

median family income of $60 000 to <$90 000



Isolate the effect of legislation on the likelihood of





supplemental MRI: estimate and odds ratio of MRI
within 9 months of mammogram in the prelegislation period versus the post-legislation period.



The crude rate of MRI increased from 12.1 per 10 000 women



(8)

or more than $120 000.

A 46% increase (OR : 1.46, CI: 1.30-1.64) in the odds of MRI
within 9 months of mammogram pre- to post-legislation.

Statistically significant increases in MRI rates



Women with dense breasts (density category C
or D) had 2.08 times (CI: 1.769-2.46) or 2.77
times (CI: 1.93-3.97) the odds respectively of
having an MRI within 9 months of a
mammogram compared with women in
category B.

20

Horny et al.,

Pre-post monthly analyses of supplemental ultrasound

2020 [34]

and MRI in 18 states.



Implementation of BDN legislation was associated with a

Not reported

statistically significant increase in the probability of downstream
breast imaging.


An increased probability of ultrasound within 30 days of screening
mammography in all BDN legislation states except for Hawaii,
Maryland, and New York (P<0.01).



An increased probability of MRI within 60 days of screening
mammography in California, North Carolina, Pennsylvania, and
Texas (OR: 1.02-1.42, P<0.002)



No significant association between adoption of BDN legislation

1.

legislation visits with ordering among post-notification

and ultrasound ordering (3.9% of pre-legislation visits vs 4.2%



legislation visits in asymptomatic women.

post-legislation visits, RR: 1.1, 95% CI: 0.3-3.6, P= 0.91).

were associated with younger patient age (RR:

No significant association between adoption of BDN legislation

0.8 per 10-year increase, 95% CI: 0.6-1.0,

and supplemental ultrasound ordering (7.1% of pre-legislation

P=0.03).

Liao et al.,

Compare ultrasound use among pre-notification

2020 [32]



visits vs 10.0% post-legislation visits, RR: 1.4, 95% CI: 0.4-4.4,




Patient-level variables:
Higher rates of screening ultrasound orders

Screening ultrasound ordered more frequently

P=0.56).

at visits in which screening mammography

Higher rates of screening ultrasound ordering were not associated

was ordered (RR: 2.3, 95% CI: 1.6-3.3,

with adoption of state notification legislation (RR: 0.7, 95% CI:

P<0.001).
2.

0.3-2.0, P=057).

Physician-level variables:
Obstetrician-gynaecologists ordered ultrasound
more frequently than other primary care
physicians (P=0.005).

3.

Practical-level variables:
Physicians in urban MSAs(10) ordered
ultrasound more frequently than physicians in
non-MSA areas (P=0.001).
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Manning et

Explore two hypothesises:

al., 2011



[23]



Rates of supplemental screening increased (0.14% vs 0.70%) after

Women with dense breasts were more likely to be

the implementation of BDN legislation.

supplementally screened than women with non-

African American women with dense breasts and non-dense

dense breasts.

in between-race differences

breasts, the rates increased from 0.2% to 0.4% and 0.8% to 3.8%,

African American women were less likely to be

The effects of racial group and breast density on the

respectively.

screened both before and after the BDN legislation;

European American women with dense breasts and non-dense

invariance tests indicated no difference in

breasts, the rates increased from 1.3% to 1.8% and 3.2% to 3.6%,

magnitude of between-race difference over time.

Whether adoption of BDN legislation moderates the
magnitude of the explanatory role of breast density



association between breast cancer risk and





supplemental screening.

respectively.


No report on statistical significance of the above changes.



5-fold post-law increase in supplemental screening rates,
attributable to the increase in the proportion of African American
women who were supplementally screened after adoption of BDN
legislation.



The direct effect of breast density on supplemental screening was
significantly different after the legislation compared with before
(∆χ2=5.93, P<0.05).

Mason et al.,

Record monthly number of MRIs performed in study

2015 [24]

institution. Compare the trends in the number of MRIs in
2011(before Henda’s law

(11)

) and 2012-2013(after



trends for all three categories of breast MRIs.


Henda’s law). Divide all breast MRIs into three
categories:


total number of breast MRIs;



total number of screening breast MRIs (defined as

After the implementation of Henda’s law, there were increased
A 23-fold increase in the number of MRIs ordered for dense
breasts compared to the pre-Henda’s law data



No report on statistical significance of these changes

studies of asymptomatic patients with no personal
history of breast cancer);


total number of screening breast MRIs ordered for
the evaluation of dense breasts (excluding high-risk

22

Not reported

patients with a strong family history of breast
cancer or who were known to be BRCA positive).
Nyante et

Compared the frequency of supplemental screening

Supplemental screening use was similar before and after the notification

New use of screening DBT in post-legislation

al., 2020

occurring pre/post legislation, stratified by whether

legislation, regardless of breast density (dense breasts: adjusted odds

period was greater for women with dense breasts

[29]

breasts were classified as dense or non-dense.

ratio (aOR

(12)

:1.01; 95%CI: 0.58-1.75); non-dense breasts: (aOR:0.63;

(versus non-dense breasts; aOR:1.15; 95% CI: 0.08-

95% CI: 0.38-1.04).

1.23).
Not reported

Parris et al.,

Comparison of cancer detection by ultrasound, and



Biopsy rate increased from 1.5% to 3.3%

2013 [25]

biopsy rate, pre/post legislation



Higher cancer detection rate with ultrasound after legislation
(0.18% post-legislation period vs 0% pre-legislation period)





Ram et al.,

Compare the ordering pattern for screening breast MRI

2018 [26]

examinations in the 30-month period before and after the

the post-legislation period to screening MRIs (376 studies)

white. Reciprocally, blacks and Asians made

BDN legislation was enacted.

performed in the pre-legislation period. No report on statistical

up a lower fraction of women receiving MRIs

significance of the change.

both before and after BDN legislation went

The frequency of breast density mentioned as an indication for the

into effect.



71.8% increase from screening MRIs (646 studies) performed in

study more than doubled after the legislation, from 8.5% to 21.1%
(P<0.0001).



Women receiving MRIs were predominantly

Female providers and specialists ordering
supplemental screening MRIs significantly
outnumbered male and primary care ordering
providers.

Saulsberry et



Difference-in-differences analysis of supplemental



Supplemental breast imaging and biopsy increased modestly in

al., 2019

imaging and biopsies before and after BDN

states with BDN legislation and changed minimally in control

[35]

legislation in 12 states enacting breast DBN

states.

legislation from 2009 to 2014 and 12 matched




Compared with pre-legislation in intervention and control states,

control states.

legislation was associated with adjusted difference-in-differences

Conducted analyses after stratifying by women in

estimates of +1.3% (P<0.0001) and +0.4% (P<0.0001) for

Connecticut and New Hampshire (control state)

supplemental imaging and biopsies, respectively, in the 6–12

versus women in all other states.

months after the legislation and difference-in-differences estimates
of +3.3% (P<0.0001) and +0.8%(P<0.0001) for supplemental
imaging and biopsies, respectively, 12–18 months after the law.
23

Not reported



Larger effects of breast density legislation on supplemental breast
imaging and breast biopsies in Connecticut than in legislation
states without insurance mandates (P<0.0001).



No statistically significant differences in the proportions of women
newly diagnosed with breast cancer in states with BDN legislation
and control states.



Sobotka et

Comparison of mammography and follow-up ultrasound

al., 2015

was made between the mean number seen monthly in

legislation period vs 42.16% post-legislation period). No report on

[27]

January through March, which preceded the enactment

statistical significance of the change

of BDN, and a mean of the months after enactment



The average rate of follow-up ultrasound increased. (17.6% pre-

With a calculated reimbursement of $225.83 per ultrasound

(separated as May to July 2014 and November to

examination, this translates to an increased reimbursement amount

December 2014).

of $4,910,899.18 to $9,848,897.96 for a given month.


Not reported

Sanders et

Compare changes in imaging volumes, intervention

al., 2016

utilisation and modality of cancer diagnosis in two

11,486). Tomosynthesis volume increased by 496% (628 vs 3,740).

[30]

periods: 18 months before and 18 months after

MRI utilisation increased by 59.3% (2,595 vs 4,134). Diagnostic

enactment of BDN legislation.

ultrasound volume increased by 29% (10,698 vs 13,847). No report

Screening ultrasound volume increased by 651% (1,530 vs

Not reported

on statistical significance of these changes.


Total core biopsies performed decreased by 3%. Ultrasound and
MRI cores biopsies increased by 3.6% and 4%, respectively.



Overall, screening-detected cancers increased by 11% after the
implementation of the BDN legislation. Cancers found by
ultrasound increased by 600% (2 versus 21, P<0.01). Cancers
found by MRI increased by 189% (9 versus 26, P<0.01).



MRI reported

to be the most efficacious examination.

Notes: (1) CI: confidence interval; (2) non-BDN states: the states without breast density notification (BDN) legislation; (3) Generic-BDN: BDN mentions breast density; (4) BDN-SS: BDN mentions breast
density and the possible benefits of supplemental screening; (5) BDN-coverage states: the states with BDN legislation and laws requiring health insurance cover for supplemental screening; (6) MRI:
magnetic resonance imaging; (7) RR: relative risk; (8) OR: odds ratio; (9) BMI: body mass index; (10) MSA: metropolitan statistical area; (11) Henda's Law: breast density notification legislation in Texas;
(12) aOR: adjusted odds ratio
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Table 3. Supplemental screening utilisation following implementation of breast density notification legislation
Study (author, year)

Supplemental screening (type)(1)

Increase in supplemental

Increase shown statistically significant

（3）

screening rates shown(2)
Aripoli et al., 2018 [22]

 (Ultrasound)





Aminawung et al., 2020 [31]

 (Ultrasound, MRI)





Busch et al., 2019 [33]

 (Ultrasound, MRI)





Chau et al.,2017 [28]

 (MRI)





Horny et al., 2020 [34]

 (Ultrasound, MRI)





Liao et al., 2020 [32]

 (Ultrasound)





Manning et al., 2019 [23]

 (Ultrasound, MRI, breast tomosynthesis)





Mason et al.， 2015 [24]

 (MRI)





Nyante el al., 2020 [29]

 (Ultrasound, MRI, breast tomosynthesis)





Parris el al., 2013 [25]

 (Ultrasound)





Ram al. al, 2018 [26]

 (Review all screening breast MRI studies performed in the





institution. The observed increase of MRI utilisation was not
limited to supplemental screening)
Saulsberry et al., 2019 [35]

 (Ultrasound, MRI, breast tomosynthesis)





Sobotka et al., 2015 [27]

 (Ultrasound)





Sanders et al., 2016 [30]

 (Unclear whether the included examinations were





supplemental screening after mammography or conducted for
other reasons)
Notes: (1) whether the study specifically classified the screening as supplemental screening (or examined the overall utility); (2) whether the study observed increases in supplemental screening rates; (3)
whether the study reported the statistical significance of differences on supplemental screening observed by the study
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Table 4. Different content/types of Breast Density Notification in eligible studies(1)
Author, years

Content/types of BDN

Results

Aripoli et al., 2018 [22]



Letter A: no notification of breast tissue density.

Patient who received letter B or C more likely to return



Letter B: notification of breast tissue density;

for ultrasound screening examination, especially those

information on benefits from additional screening

received letter C.



Letter C: notification of breast tissue density;
benefits from additional screening; a follow-up
courtesy telephone call.

Busch et al., 2019 [33]



Non‐BDN States(2)

BDN legislation was associated with increased use of



Generic BDN States(3): notification of breast

ultrasound, and cancer detection, after implementation

tissue density

only when notification of the possible benefits of



BDN‐SS States : notification of breast tissue
(4)

supplemental screening was required.

density; benefits from additional screening
Aminawung et al, 2020 [31]



Non‐BDN States

Women in BDN‐coverage states were more likely to



Generic BDN States

discuss supplemental screening with their providers,



BDN‐SS States



BDN‐coverage States : Breast density

and to undergo supplemental screening, compared to
(5)

women in other states.

notification with insurance overage of
supplemental screening
Saulsberry et al., 2019 [35]



12 BDN states

Impact of BDN legislation on the use of supplemental



12 matched control states without BDN

breast imaging and breast biopsies was amplified when



One BDN‐coverage States: Connecticut

coupled with mandatory insurance coverage.

Note: (1) studies which examine the effect of different types of BDN/BDN legislation on supplemental screening; (2) non-BDN states: the states without breast density notification (BDN) legislation; (3)
Generic-BDN: BDN mentions breast density; (4) BDN-SS: BDN mentions breast density and the possible benefits of supplemental screening; (5) BDN-coverage states: the states with BDN legislation and
laws requiring health insurance cover for supplemental screening
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Supplemental file 1. Search strategies
OVID Medline

OVID Pre-Medline

OVID Embase

Cochrane Database of

CINAHL

PubMed
((breast*[Title])

SRs
1. breast*.ti.

1. breast*.ti.

1. breast*.ti.

1. breast*.ti.

S1

2. mammogr*.ti.

2. mammogr*.ti.

2. mammogr*.ti.

2. mammogr*.ti.

TI mammogr*

(mammograph*[Title]))

AND

3. 1 or 2

3. 1 or 2

3. 1 or 2

3. 1 or 2

S2

(dens*[Title])

AND

4. dens*.ti.

4. dens*.ti.

4. dens*.ti.

4. dens*.ti.

AB legislat* OR AB

(((((notif*[Title/Abstract])

OR

5. notif*.mp

5. notif*.mp

5. notif*.mp

5. notif*.mp

law* OR AB bill* or

(legislat*[Title/Abstract])

OR

6. legislat*.mp

6. legislat*.mp

6. legislat*.mp

6. legislat*.mp

AB act*

(law[Title/Abstract])

OR

7. law*.mp

7. law*.mp

7. law*.mp

7. law*.mp

S3

(bill[Title/Abstract)

OR

8. bill*.mp

8. bill*.mp

8. bill*.mp

8. bill*.mp

supplement* OR AB

(act[Title/Abstract])))))

9. act*.mp

9. act*.mp

9. act*.mp

9. act*.mp

adjunc*

(((((((supplement*[Title/Abstract]) OR

10. 5 or 6 or 7 or 8 or

10. 5 or 6 or 7 or 8 or

10. 5 or 6 or 7 or 8 or

10. 5 or 6 or 7 or 8 or

addition* OR AB plus

(adjunc*[Title/Abstract])

OR

11. supplement*.mp

11. supplement*.mp

11. supplement*.mp

11. supplement*.mp

OR AB ultras* OR

(addition*[Title/Abstract])

OR

12. adjunc*.mp

12. adjunc*.mp

12. adjunc*.mp

12. adjunc*.mp

AB tomo* OR AB

(plus[Title/Abstract])

OR

13. addition*.mp

13. addition*.mp

13. addition*.mp

13. addition*.mp

MRI

(ultras*[Title/Abstract])

OR

14. plus.mp

14. plus.mp

14. plus.mp

14. plus.mp

S4 TI dens*

(tomo*[Title/Abstract])

OR

15. ultras*.mp

15. ultras*.mp

15. ultras*.mp

15. ultras*.mp

S5

(MRI[Title/Abstract]))))))) Filters: from

16. MRI.mp

16. MRI.mp

16. MRI.mp

16. MRI.mp

AND S3 AND S4

17. tomo*.mp

17. tomo*.mp

17. tomo*.mp

17. tomo*.mp

18. 11 or 12 or 13 or 14

18. 11 or 12 or 13 or 14

18. 11 or 12 or 13 or 14

18. 11 or 12 or 13 or 14

or 15 or 16 or 17

or 15 or 16 or 17

or 15 or 16 or 17

or 15 or 16 or 17

19. 3 and 4 and 10 and

19. 3 and 4 and 10 and

19. 3

19.

18

18

ti=title; mp=multi-purpose,

AB= abstract

TI breast* OR
AB notif* OR

AB
OR

AB

SI AND S2

2009 - 2020

OR

AND

Supplemental file 2. Eligibility criteria

Types of studies

Inclusion

Exclusion

Empirical studies, published in full, that consider the impact or effect of legislation for

Hypothetical studies or studies that measure intention;

breast density notification on supplemental screening practice

protocols, review papers, editorials, commentary/discussion
papers, conference abstracts

Population

Women screened for breast cancer who have been informed they have dense breast tissue

Women being screened who do not have dense breast tissue

(or implied inclusion of these women, i.e. legislation/notification process involved or

(or

analysed)

legislation/notification process involved or analysed)

Types of setting

Any type of screening setting

Study

Breast density legislation or notification

factor

(intervention)
Outcome factor



Primary outcome: supplemental screening practice: uptake of breast
tomosynthesis, MRI or ultrasound
*Papers MUST report the primary outcome to be eligible. A proportion of these
will ALSO report secondary outcomes



Secondary outcomes: recall for further assessment for each supplementary
modality (%/proportion), biopsy (%/proportion) for each supplementary modality,
cancer detection (%/proportion) for each supplementary modality, cost ($) per
patient, per study and/or per cancer detected, patient report outcome measures
related to additional screening, e.g. anxiety of recall (if available)

implied

exclusion

of

these

women,

i.e.

NO

